Asset profile
PF-04634817
Unknown / undisclosed
Evidence outlook · program status
Discontinued, after a negative readout
PF-04634817 was Pfizer's oral CCR2/CCR5 chemokine receptor antagonist, taken to phase 2 in diabetic nephropathy and diabetic macular edema. This Pfizer-authored report of the diabetic nephropathy phase 2 states that clinical development was discontinued because the albuminuria reduction was too modest; the drug had also failed non-inferiority against ranibizumab in diabetic macular edema. The paper gives no date for the decision. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.